Phase 1 Heart Disease Trial, Recruiting NCT06164730 Sponsor: Verve Therapeutics, Inc. Condition: Heart Disease
Back to Heart Disease

Phase 1 Heart Disease Trial, Recruiting

NCT06164730
Recruiting Phase 1 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with heterozygous familial hypercholesterolemia (an inherited condition that causes high cholesterol) or with early-onset coronary artery disease (heart disease that developed at a younger age than typical)

Who may not be able to join:

  • People who have homozygous familial hypercholesterolemia (a more severe inherited form of high cholesterol involving two copies of the faulty gene, rather than one)
  • People who currently have, or have had in the past, a long-term liver condition or disease
  • People who are currently being treated with a type of cholesterol-lowering medicine called a PCSK9 inhibitor, or who have been treated with one within a certain period of time before the trial (confirm exact timeframe with trial site)
  • People whose blood test results show certain abnormal values as defined by the trial's medical guidelines (confirm specifics with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company

Phone: 317-615-4559

Australian sites

Clinical Study Center, Adelaide,
Clinical Study Center, Melbourne,
Clinical Study Center, Sydney,

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Verve Therapeutics, Inc.
Registry
ClinicalTrials.gov
Start date
30 April 2024
Est. completion
1 August 2026

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada 🇮🇱 Israel 🇳🇿 New Zealand 🇬🇧 United Kingdom 🇺🇸 United States

3 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov